A phase i study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 21-27

  Gordon, Michael S ^a   Ilaria Jr , Robert ^b   De Alwis, Dinesh P ^b,g   Mendelson, David S ^a   McKane, Scott ^c,e   Wagner, Margaret M ^b   Look, Katherine Y ^b,f   Lorusso, Patricia M ^d  

^a Pinnacle Oncology Hematology   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c I3 Inc   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e NAMSA Inc   (United States)

^f GENENTECH INC   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dose escalation; LY573636; Phase I; Solid tumors; Tasisulam

Indexed keywords

TASISULAM;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPOXIA; LEUKOPENIA; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SULFONAMIDES;

EID: 84872320891     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1917-8     Document Type: Article

References (13)

1. World Health Organization (2011) Fact Sheet No 297, October 2011, Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed 9 Dec 2011
2. Corbett TH, Valeriote FA, Polin L et al (1992) Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. In: Valeriote FA, Corbett TH, Baker LH (eds) Cytotoxic anticancer drugs: models and concepts for drug discovery and development. Kluwer Academic Publishers, Norwell, MA, pp 35-87
3. Haritunians T, Gueller S, O'Kelly J, Ilaria R Jr, Koeffler HP (2008) Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. Oncol Rep 20:1237-1242
4. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092
5. Simon GR, Ilaria RL Jr, Sovak MA et al (2011) A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol 68:1233-1241
6. Ratain MJ, Mick R, Schilsky RL, Siegler M (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637-1643
7. National Cancer Institute (1999) Cancer Therapy Evaluation Program, Common Toxicity Criteria, version 2.0. http://ctep.info.nih.gov/ protocolDevelopment/electronic-applications/docs/ctcv20-4-30-992.pdf. Accessed 9 Dec 2010
8. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
9. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST (2000) Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278-1283
10. Sterling K (1951) The turnover rate of serum albumin in man as measured by I131-tagged albumin. J Clin Invest 30:1228-1237
11. Rowland M, Tozer TN (1995) Clinical pharmacokinetics, concepts and applications, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, PA, p 149
12. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051-1065
13. Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP, Zimmermann A, Brown MP, Ilaria RL Jr, Millward MJ (2011) A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. doi: 10.1002/cncr.26068. [Epub ahead of print]